Rein Therapeutics, Inc. Research and Development Expense
Rein Therapeutics, Inc. (RNTX) reported Research and Development Expense of $3.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Rein Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.64M, a 15.24% decline year-over-year.
- Rein Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $3.07M, a 0.62% increase year-over-year.
- Rein Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $2.00M, a 39.77% decline year-over-year.
- Rein Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $1.68M, a 54.84% decline year-over-year.
- Rein Therapeutics, Inc. research and development expense for fiscal 2025 was $11.03M, a 22.59% decline from fiscal 2024.
- Rein Therapeutics, Inc. research and development expense for fiscal 2024 was $14.25M, a 257.00% increase from fiscal 2023.
- Rein Therapeutics, Inc. research and development expense for fiscal 2023 was $3.99M, a 77.79% decline from fiscal 2022.
- Rein Therapeutics, Inc. research and development expense for fiscal 2022 was $17.97M, a 5.64% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.64M 10-Q · filed 2026-08-14 | $6.71M 10-Q · filed 2026-08-14 | $8.71M derived: sum of 3 quarters · filed 2026-08-14 | $10.39M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $3.07M 10-Q · filed 2026-05-15 | $5.07M derived: sum of 2 quarters · filed 2026-05-15 | $6.75M derived: sum of 3 quarters · filed 2026-05-15 | $11.05M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.68M derived: sum of 2 quarters · filed 2026-03-26 | $7.97M derived: sum of 3 quarters · filed 2026-08-14 | $11.03M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $1.68M 10-Q · filed 2025-11-14 | $5.97M derived: sum of 2 quarters · filed 2026-08-14 | $9.03M 10-Q · filed 2025-11-14 | $12.35M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $4.29M 10-Q · filed 2026-08-14 | $7.35M 10-Q · filed 2026-08-14 | $10.67M derived: sum of 3 quarters · filed 2026-08-14 | $14.39M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $3.05M 10-Q · filed 2026-05-15 | $6.38M derived: sum of 2 quarters · filed 2026-05-15 | $10.10M derived: sum of 3 quarters · filed 2026-05-15 | $13.84M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $3.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.04M derived: sum of 2 quarters · filed 2026-03-26 | $10.79M derived: sum of 3 quarters · filed 2026-03-26 | $14.25M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $3.72M 10-Q · filed 2025-11-14 | $7.46M derived: sum of 2 quarters · filed 2025-11-14 | $10.93M 10-Q · filed 2025-11-14 | $12.90M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $3.74M 10-Q · filed 2025-08-14 | $7.20M 10-Q · filed 2025-08-14 | $9.18M derived: sum of 3 quarters · filed 2025-08-14 | $9.20M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $3.46M 10-Q · filed 2025-05-15 | $5.43M derived: sum of 2 quarters · filed 2025-05-15 | $5.46M derived: sum of 3 quarters · filed 2025-05-15 | $5.64M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $1.99M derived: sum of 2 quarters · filed 2025-04-07 | $2.18M derived: sum of 3 quarters · filed 2025-04-07 | $3.99M 10-K · filed 2025-04-07 | |
| 2023-09-30 | $22.00K 10-Q · filed 2024-11-14 | $209.00K derived: sum of 2 quarters · filed 2024-11-14 | $2.02M 10-Q · filed 2024-11-14 | $4.42M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $187.00K 10-Q · filed 2024-08-14 | $2.00M 10-Q · filed 2024-08-14 | $4.40M derived: sum of 3 quarters · filed 2024-08-14 | $8.64M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $1.81M 10-Q · filed 2024-05-15 | $4.21M derived: sum of 2 quarters · filed 2024-05-15 | $8.45M derived: sum of 3 quarters · filed 2024-05-15 | $13.88M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $6.64M derived: sum of 2 quarters · filed 2024-04-15 | $12.07M derived: sum of 3 quarters · filed 2024-04-15 | $17.97M 10-K · filed 2024-04-15 | |
| 2022-09-30 | $4.24M 10-Q · filed 2023-10-13 | $9.67M derived: sum of 2 quarters · filed 2023-10-13 | $15.56M 10-Q · filed 2023-10-13 | $20.13M derived: sum of 4 quarters · filed 2023-10-13 | |
| 2022-06-30 | $5.43M 10-Q · filed 2023-08-11 | $11.33M 10-Q · filed 2023-08-11 | $15.89M derived: sum of 3 quarters · filed 2023-08-11 | $20.16M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $5.89M 10-Q · filed 2023-05-08 | $10.45M derived: sum of 2 quarters · filed 2023-05-08 | $14.73M derived: sum of 3 quarters · filed 2023-05-08 | $18.59M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $8.84M derived: sum of 2 quarters · filed 2023-03-20 | $12.69M derived: sum of 3 quarters · filed 2023-03-20 | $17.01M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $4.28M 10-Q · filed 2022-11-01 | $8.13M derived: sum of 2 quarters · filed 2022-11-01 | $12.45M 10-Q · filed 2022-11-01 | $14.37M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $3.85M 10-Q · filed 2022-08-15 | $8.17M 10-Q · filed 2022-08-15 | $10.09M derived: sum of 3 quarters · filed 2022-08-15 | $12.78M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $4.32M 10-Q · filed 2022-05-05 | $6.24M derived: sum of 2 quarters · filed 2022-05-05 | $8.93M derived: sum of 3 quarters · filed 2022-05-05 | $11.41M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $1.93M 10-K · filed 2021-03-24 | $4.61M derived: sum of 2 quarters · filed 2021-11-12 | $7.10M derived: sum of 3 quarters · filed 2021-11-12 | $11.17M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $2.68M 10-Q · filed 2021-11-12 | $5.17M derived: sum of 2 quarters · filed 2021-11-12 | $9.24M 10-Q · filed 2021-11-12 | $13.95M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $2.49M 10-Q · filed 2021-08-11 | $6.56M 10-Q · filed 2021-08-11 | $11.27M derived: sum of 3 quarters · filed 2021-08-11 | $15.74M derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $4.07M 10-Q · filed 2021-05-11 | $8.78M derived: sum of 2 quarters · filed 2021-05-11 | $13.25M derived: sum of 3 quarters · filed 2021-05-11 | $17.56M derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | $4.71M 10-K · filed 2021-03-24 | $9.18M derived: sum of 2 quarters · filed 2021-03-24 | $13.49M derived: sum of 3 quarters · filed 2021-03-24 | $17.66M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $4.47M 10-K · filed 2021-03-24 | $8.78M derived: sum of 2 quarters · filed 2021-03-24 | $12.95M 10-Q · filed 2020-11-12 | $16.91M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2019-06-30 | $4.30M 10-K · filed 2021-03-24 | $4.30M 10-Q · filed 2019-08-06 | $8.48M 10-Q · filed 2020-08-05 | $12.44M derived: sum of 3 quarters · filed 2021-03-24 | $16.76M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | $4.17M 10-K · filed 2021-03-24 | $8.13M derived: sum of 2 quarters · filed 2021-03-24 | $12.46M derived: sum of 3 quarters · filed 2021-03-24 | $17.78M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2018-12-31 | $3.96M 10-K · filed 2020-03-30 | $8.28M derived: sum of 2 quarters · filed 2020-03-30 | $13.60M derived: sum of 3 quarters · filed 2020-03-30 | $18.45M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $4.32M 10-K · filed 2020-03-30 | $9.64M derived: sum of 2 quarters · filed 2020-03-30 | $14.49M 10-Q · filed 2019-11-07 | $18.80M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2018-06-30 | $5.32M 10-K · filed 2020-03-30 | $10.17M 10-Q · filed 2019-08-06 | $14.48M derived: sum of 3 quarters · filed 2020-03-30 | $18.30M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2018-03-31 | $4.85M 10-K · filed 2020-03-30 | $9.16M derived: sum of 2 quarters · filed 2020-03-30 | $12.98M derived: sum of 3 quarters · filed 2020-03-30 | $16.14M derived: sum of 4 quarters · filed 2020-03-30 | |
| 2017-12-31 | $4.31M 10-K · filed 2019-03-29 | $8.14M derived: sum of 2 quarters · filed 2019-03-29 | $11.30M derived: sum of 3 quarters · filed 2019-03-29 | $14.24M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $3.83M 10-K · filed 2019-03-29 | $6.99M derived: sum of 2 quarters · filed 2019-03-29 | $9.93M 10-Q · filed 2018-11-07 | $13.02M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-06-30 | $3.16M 10-K · filed 2019-03-29 | $6.10M 10-Q · filed 2018-08-07 | $9.20M derived: sum of 3 quarters · filed 2019-03-29 | $11.80M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2017-03-31 | $2.94M 10-K · filed 2019-03-29 | $6.03M derived: sum of 2 quarters · filed 2019-03-29 | $8.64M derived: sum of 3 quarters · filed 2019-03-29 | $10.72M derived: sum of 4 quarters · filed 2019-03-29 | |
| 2016-12-31 | $3.09M 10-K · filed 2018-04-02 | $5.70M derived: sum of 2 quarters · filed 2018-04-02 | $7.78M derived: sum of 3 quarters · filed 2018-04-02 | $10.28M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $2.60M 10-K · filed 2018-04-02 | $4.69M derived: sum of 2 quarters · filed 2018-04-02 | $7.18M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $2.09M 10-K · filed 2018-04-02 | $4.58M 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | $2.49M 10-K · filed 2018-04-02 | ||||
| 2015-12-31 | $7.83M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |